Recent Health Policy Research

• Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement
  decision-making: to lambda and beyond. Value in Health 2008; 11: 771-83.
• Gavura S, Miller E, Rocchi A. Different drugs, different thresholds: a social good? Panel presentation at
  CADTH Symposium 2009.
• Rocchi A, Miller E. CEDAC recommendations: patterns and predictors. Presented at the CADTH Symposium
  2009 and CAPT 2009.
• Rocchi A, Miller E. CEDAC recommendations: does cost-effectiveness matter? Presented at the CADTH
  Symposium 2008 and ISPOR 2008.
• Rocchi A. Who pays determines how you play: designing drug submissions to maximize reimbursement.
  Strategy Institute, December 2007.

Recent Economic Evaluations

• Miller E, FitzGerald JM. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose
  combination strategies – a Canadian economic evaluation. Can J Clin Pharmacol 2008;15(2) Summer:e165-
  e176.
• Miller E, Sears MR, McIvor A, Liovas A. Canadian economic evaluation of budesonide-formoterol as mainte-
  nance and reliever treatment in patients with moderate to severe asthma. Can Respir J 2007;14(5):269-275.
• Rocchi A, O’Connor P. Cost-utility analysis of Tysabri (natalizumab) in relapsing-remitting multiple sclerosis
  (RRMS). Presented at CAPT 2007.
• Rocchi A, Kim T. Fulvestrant: economic evaluation for the Canadian setting. Presented at CAPT 2007.
• Rocchi A, Verma S. Economic evaluation of an astrozole versus tamoxifen in adjuvant treatment of early breast
  cancer. Support Care Cancer 2006; 14; 917-27.